OncoMatch/Clinical Trials/NCT07443475
Electrochemotherapy for Recurrent Vulvar Cancer
Is NCT07443475 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies non-drug interventions for vulvar cancer.
This phase I/II interventional study evaluates the effectiveness and safety of electrochemotherapy (ECT) as neoadjuvant treatment for local recurrence of vulvar cancer. Electrochemotherapy combines intravenous administration of bleomycin with delivery of electric pulses to the tumor area, increasing drug uptake into cancer cells. The main goal is to assess tumor response and reduce the need for mutilating surgical procedures, thereby improving quality of life in women with recurrent vulvar cancer. Participants will be followed prospectively and treatment outcomes will be evaluated using RECIST criteria and adverse events using CTCAE v5.0.
Check if I qualifyExtracted eligibility criteria
Cancer type
Cervical Cancer
Performance status
KARNOFSKY OR WHO 70–2
Karnofsky performance status ≥ 70 or WHO performance status ≤ 2
Prior therapy
Cannot have received: bleomycin (bleomycin)
Exception: cumulative dose < 400 mg/m²
Prior cumulative bleomycin dose ≥ 400 mg/m²
Lab requirements
Blood counts
Major coagulation disorders not responding to standard therapy [excluded]
Kidney function
Chronic renal impairment (creatinine > 150 µmol/L) [excluded]
Cardiac function
Severe cardiac disease [excluded]
Life-threatening infection and/or severe cardiac, hepatic, or other systemic disease; Major coagulation disorders not responding to standard therapy; Chronic renal impairment (creatinine > 150 µmol/L)
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify